Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Agile Therapeutics Equity Warrants
AGXRW
Healthcare
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system...
, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:AGXRW)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 2:35am
Agile Therapeutics, Inc. (AGRX): Executing on Commercializat
https://beyondspx.com/2024/08/02/agile-therapeutics-inc-agrx-executing-on-commercialization-strategy-poised-for-continued-growth/
(270)
•••
whytestocks
X
Post by
whytestocks
on Jul 15, 2024 11:02pm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV
Just In: $AGRX SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders | BenzingaNEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 26, 2023 8:05am
New Press Release - Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2023 financial results before the market open on Thursday, November 9, 2023...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 04, 2023 4:30pm
New Press Release - Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to the Company’s newly appointed Chief Financial Officer, Scott Coiante. In accordance with Nasdaq...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 03, 2023 8:19am
AGRX....never say never but what I can see
that they've been "Walkin the Dog" since 09/21/23 and the 2nd buy recommendation. Sure would be nice to see this continue GLTA
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 02, 2023 3:11pm
AGRX....just a little under 1 hr to go til the close
Excuse me Mr. M.....will you be high closing this today???? Either way.....I'm good ; )
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 02, 2023 10:26am
AGRX....They say "The Trend is Your Friend"
Share price trending higher last week after the 2nd Buy recommendation I guess slow and steady works....now $2.59 h.o.d Volume still low Maybe next week it will run
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 29, 2023 2:02pm
AGRX....Your sooooo brave Mr. M
R u worried about all the naked short who want your head ??? LoL
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 29, 2023 12:33pm
AGRX....whats it going to be Mr. M ???
U going to pacify the Masses and high close this today??? All Bagholders...oops ...pardon me ....Shareholders are curious if you have an ounce of integrity???
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 28, 2023 2:55pm
AGRX.... My last post on this was deleted by none other than
SH Admin......because I said Bull Feces Sheesh....can't they handle the truth???? AGRX.....Sorry ol Buddy.....You've lost all credibility
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 28, 2023 1:58pm
AGRX ...LoL....some kind of Buy recommendation eh?
Nobody wants this p.o.s.....Zero volume....WTF
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 28, 2023 12:47pm
AGRX....And just to let u know...if ur silly enough to buy
These guys use After Hours trading to move the share price and blow off their paper So be prepared ....JMHO GLTU
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 28, 2023 12:25pm
AGRX..... Oh Nooo!! Another Buy recommendation...gulp!
The last time Wainwright posted a NR with a buy recommendation was on 07/05/23....The Maddapakkas let this bleed for months. I just don't trust these guys.....NR is below my chart Note: big fat
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Sep 28, 2023 9:02am
New Press Release - Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. The firm's focus and area of expertise is in...
read article.
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 21, 2023 12:37pm
AGRX....just a waste of my time
LIes lies lies...tell me sweet little lies!!!!
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
Featured News Links
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden